Early phase 1 trial results using a novel chimeric antigen receptor T-cell therapy manufactured at University of Colorado show encouraging efficacy for adults with relapsed or refractory B-cell non-Hodgkin lymphoma.
Data presented at American Association for Cancer Research Annual Meeting revealed that six of seven patients had an initial complete response to the investigational cell therapy and remain alive as of the study’s data cutoff date.
Developing a new CD19-directed CAR-T for patients with B-cell non-Hodgkin lymphoma is necessary despite an already crowded market of commercially